Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease
Bahnasawy, S., El Gammal, N., El Attar, N., El-Gebaly, A. (2023). Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease. EKB Journal Management System, 91(1), 5345-5352. doi: 10.21608/ejhm.2023.305534
Sherif Ali Mohamed Bahnasawy; Nahla El Sayed El Gammal; Nahla Ibrahim El Attar; Ahmed M. El-Gebaly. "Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease". EKB Journal Management System, 91, 1, 2023, 5345-5352. doi: 10.21608/ejhm.2023.305534
Bahnasawy, S., El Gammal, N., El Attar, N., El-Gebaly, A. (2023). 'Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease', EKB Journal Management System, 91(1), pp. 5345-5352. doi: 10.21608/ejhm.2023.305534
Bahnasawy, S., El Gammal, N., El Attar, N., El-Gebaly, A. Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease. EKB Journal Management System, 2023; 91(1): 5345-5352. doi: 10.21608/ejhm.2023.305534

Liver Fatty Acid-binding Protein (L-FABP) as a Diagnostic Marker for Non-alcoholic Fatty Liver Disease

The Egyptian Journal of Hospital Medicine
Article 246, Volume 91, Issue 1, April 2023, Page 5345-5352  XML PDF (665.08 K)
DOI: 10.21608/ejhm.2023.305534
View on SCiNiTO View on SCiNiTO
Authors
Sherif Ali Mohamed Bahnasawy* ; Nahla El Sayed El Gammal; Nahla Ibrahim El Attar; Ahmed M. El-Gebaly
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide; thus, an early and accurate diagnosis will improve the prognosis therapeutic interventions.
Aim: To assess the diagnostic value of liver fatty acid binding protein (L-FABP) for liver injury in non-alcoholic fatty liver disease (NAFLD).
Patients and methods: This prospective case-control study was conducted at the Hepatology, Gastroenterology, and Infectious Diseases Clinics, Zagagzig University Hospitals, Egypt on 60 participants divided into three groups: 20 members of the NAFLD in group I had high liver enzymes, 20 members of the NAFLD in group II had normal liver enzymes and 20 members of the healthy control group in group III. L-FABP was measured in all subjects.
Results: Regarding L-FABP levels, all of the examined groups showed a significant statistical difference; group I had higher levels than groups II and III, whereas group II had higher levels than group III.
Conclusion: The diagnostic biomarker fatty acid-binding liver protein is very useful for NAFLD and a good diagnostic tool of fatty liver injury as its concentrations reflect the level invasion of fat into the liver tissue.
Statistics
Article View: 136
PDF Download: 362